Vismodegib 150 mg

DRUG4 trials

Sponsors

Genentech, Inc., Samsung Medical Center

Conditions

Basal Cell CarcinomaMetastatic Colorectal CancerOvarian CancerStomach Neoplasms

Phase 2

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer

CompletedNCT00636610

Genentech, Inc.Metastatic Colorectal Cancer

Start: 2008-05-31End: 2010-12-31Updated: 2017-06-08

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission

CompletedNCT00739661

Genentech, Inc.Ovarian Cancer

Start: 2008-12-31End: 2010-11-30Updated: 2017-06-08

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

CompletedNCT00833417

Genentech, Inc.Basal Cell Carcinoma

Start: 2009-02-10End: 2014-04-09Updated: 2026-05-11

Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression

CompletedNCT03052478

Samsung Medical CenterStomach Neoplasms

Start: 2017-02-10End: 2020-09-10Updated: 2021-06-08

Related Papers

Advanced Basal Cell Carcinoma: A Narrative Review on Current Systemic Treatments and the Neoadjuvant Approach.

2025-06-01

Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies.

2024-06-195 citations

Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm, phase-II trial

Journal of Cancer2022-01-016 citations

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

2017-05-16266 citations

Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.

2016-09-0121 citations

Vismodegib Improved DOR in mBCC and laBCC

MD Conference Express2014-11-01

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study.

Journal of Clinical Oncology2014-05-2024 citations

Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression.

Journal of Clinical Oncology2014-05-209 citations

Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.

Journal of Clinical Oncology2014-05-205 citations

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

2012-06-01991 citations